воскресенье, 3 апреля 2011 г.

PsychoGenics Announces Positive Phase-IIa For Its First-in-Class Partial 5-HT1A - 5-HT1B Receptor Agonist In ADHD

PsychoGenics Inc. announced positive data from its randomized, placebo controlled, multicenter, Phase IIa trial of eltoprazine, the company's lead partial 5-HT1A - 5-HT1B receptor agonist, in adult patients with Attention Deficit/ Hyperactivity Disorder (ADHD). The primary objective of the exploratory study was to compare the effects of two doses of eltoprazine with placebo in a cross-over design on the symptoms of ADHD in adults using the total scores from the ADHD Rating Scale-Version IV.


The compound achieved a reduction in the ADHD-RS-IV total score of 42% from baseline compared to placebo (p

Комментариев нет:

Отправить комментарий

Постоянные читатели